Prominent Players - Protein A Resin Industry

Over the course of the forecast period, the worldwide protein A resin market is anticipated to rise due to the approval of monoclonal antibodies for the treatment of various disorders. For instance, the World Health Organisation (WHO) prequalified trastuzumab, a monoclonal antibody used to treat early-stage breast cancer, as its first biosimilar drug in December 2019. Trastuzumab typically costs $20,000 USD. Trastuzumab biosimilars, on the other hand, are typically 65% less expensive than the original. Additionally, it is anticipated that the increase of chronic disorders would support the expansion of the protein A resin market globally. For instance, the American Cancer Society predicts that there will be 606,880 cancer deaths and 1,762,450 new cancer cases in the United States in 2019.

The world's Protein the market for resin is predicted to be worth US$ 511.7 million in 2020 and US$ 907.3 million by the end of 2027.

Leading Companies in the Protein A Resin Industry:

GE Healthcare:

1. A provider of ground-breaking medical technologies and services is GE Healthcare. It focuses on biopharmaceutical manufacturing technologies, computerised data management, performance enhancement, medical equipment, and performance services. It also specialises in medical imaging, information technologies, medical diagnostics, patient monitoring systems, drug development, and performance services. Chicago, Illinois serves as the company's headquarters. It was established in 1892. It pursues an aggressive acquisition strategy and concentrates on forming alliances with healthcare industry titans in an effort to strengthen the business' position in developing markets and increase the scope of its life sciences offerings.

Thermo Fisher Scientific:

2. Thermo Fisher Scientific sells reagents for life sciences, laboratory supplies, and equipment for diagnostics. As of mid-2022, the company operates through four segments: analytical technologies (15% of sales); speciality diagnostic products (10% of revenues); life science solutions (30% of revenues); and lab goods and services, which includes CRO services (51% of revenues). Built in 1956. United States headquarters.

Repligen:

3. Global life sciences business Repligen Corp. It creates and markets cutting-edge bioprocessing systems and technology that boost manufacturing flexibility and efficiency for biological pharmaceuticals. Customers of the business include international contract manufacturers, life science businesses, and biopharmaceutical companies on a global scale. Through a direct commercial organisation in the United States, Europe, and Asia as well as through strategic partners in a few areas, Repligen offers its products internationally. North America is where the corporation generates the majority of its revenue. Born in 1981. United States headquarters.  FlexBiosys Inc. is acquired by Repligen.

Tosoh Bioscience:

4. Built in 1935. Head office in Japan. Petrochemical, plastic, and chemical-based goods are all produced and sold by Tosoh Corp. By product category, the company divides itself into four areas. The Petrochemical section sells olefins and polymers, such as ethylene and polyvinyl chloride, which are used to create plastics for a range of end purposes. This segment generates more revenue than any other segment. The Chlor-Alkali section offers goods for treating water as well as caustic soda, which is used to produce soap. The Specialty section offers a range of zirconia products, clinical diagnostics tools, battery materials and bromine-based flame retardants for electronics.  Semba Biosciences, a privately held Wisconsin company, was acquired by Tosoh Bioscience LLC in full today.

EMD Millipore:

5. Supplier of goods and services for the biological sciences. Innovative goods from the business are utilised in research, development, and production of pharmaceutical and biotechnological drug therapies, as well as in research and application laboratories, allowing customers to access high-quality services. Established in 1954. Head office in the United States.

Novasep:

6. A chromatography process equipment division operator. The company specialises in high-pressure, multi-use applications for tiny molecules such oligonucleotides, peptides, and insulin and offers resin-based batch and enhanced chromatography systems. French headquarters are in Lyon. Bridgepoint, the company that now owns a majority of both Axplora and Novasep Process Solutions, is in favour of the proposed sale.

GenScript Biotech Corporation:

7. GenScript Biotech is a Chinese company that offers services and goods for life science research. It was established in 2002 and is most recognised for its gene synthesis skills, which are frequently employed by academia, biotech firms, and pharmaceutical firms all around the world. Life science research services and products, biologics development services under the ProBio brand, and industrial enzymes under the Bestzyme brand are some of its business segments. Created in 2002. United States headquarters.  Expanding its oligonucleotide and peptide production facility in China is GenScript.

*Definition:

Protein A resin is a high-affinity chromatography medium. It’s used for the one-step purification of monoclonal antibody products (mAb) and immunoglobulins from a cell culture media.